[go: up one dir, main page]

AU2003302919A1 - Pyridine derivatives as jnk inhibitors and their use - Google Patents

Pyridine derivatives as jnk inhibitors and their use

Info

Publication number
AU2003302919A1
AU2003302919A1 AU2003302919A AU2003302919A AU2003302919A1 AU 2003302919 A1 AU2003302919 A1 AU 2003302919A1 AU 2003302919 A AU2003302919 A AU 2003302919A AU 2003302919 A AU2003302919 A AU 2003302919A AU 2003302919 A1 AU2003302919 A1 AU 2003302919A1
Authority
AU
Australia
Prior art keywords
pyridine derivatives
jnk inhibitors
jnk
inhibitors
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003302919A
Inventor
Elisabeth Kallin
Niklas Plobeck
Britt-Marie Swahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2003302919A1 publication Critical patent/AU2003302919A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2003302919A 2002-12-09 2003-12-08 Pyridine derivatives as jnk inhibitors and their use Abandoned AU2003302919A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0203654-9 2002-12-09
SE0203654A SE0203654D0 (en) 2002-12-09 2002-12-09 New compounds
PCT/SE2003/001911 WO2004052880A1 (en) 2002-12-09 2003-12-08 Pyridine derivatives as jnk inhibitors and their use

Publications (1)

Publication Number Publication Date
AU2003302919A1 true AU2003302919A1 (en) 2004-06-30

Family

ID=20289817

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003302919A Abandoned AU2003302919A1 (en) 2002-12-09 2003-12-08 Pyridine derivatives as jnk inhibitors and their use

Country Status (5)

Country Link
AR (1) AR042316A1 (en)
AU (1) AU2003302919A1 (en)
SE (1) SE0203654D0 (en)
TW (1) TW200417546A (en)
WO (1) WO2004052880A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
HK1042251B (en) 1999-01-13 2012-07-20 Bayer Healthcare Llc Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
EP1478358B1 (en) 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
UY28213A1 (en) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp NEW CYANOPIRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS.
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
PT1626714E (en) 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp DIARILURIES FOR PDGFR MEDICATED DISEASES
DE602004010407T2 (en) 2003-07-23 2008-10-16 Bayer Pharmaceuticals Corp., West Haven FLUORO-SUBSTITUTED OMEGA-CARBOXYARYLDIPHENYL-UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND SUFFERING
WO2005118543A1 (en) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. Kinase inhibitor and use thereof
GB0428514D0 (en) * 2004-12-31 2005-02-09 Prosidion Ltd Compounds
EP2021338A1 (en) * 2006-05-09 2009-02-11 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
CN101611007A (en) * 2006-12-20 2009-12-23 先灵公司 Novel JNK Inhibitors
AU2007336933A1 (en) * 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections
MX2010000617A (en) 2007-07-17 2010-05-17 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor.
EP2253618A1 (en) * 2008-02-27 2010-11-24 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
AU2010232670B2 (en) 2009-04-03 2015-07-09 F. Hoffmann-La Roche Ag Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
EP2308866A1 (en) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazoles and their use as fungicides
MA33975B1 (en) 2009-11-06 2013-02-01 Plexxikon Inc COMPOUNDS AND METHODS FOR MODULATING KINASES AND THEIR INDICATIONS FOR USE
AU2011303597A1 (en) * 2010-09-17 2013-04-11 Purdue Pharma L.P. Pyridine compounds and the uses thereof
WO2012101063A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
WO2012101064A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
HUE040136T2 (en) 2011-02-07 2019-02-28 Plexxikon Inc Compounds and Methods for Kinase Modulation and Their Indications
TWI558702B (en) 2011-02-21 2016-11-21 普雷辛肯公司 Solid forms of a pharmaceutically active substance
AR086992A1 (en) 2011-06-20 2014-02-05 Bayer Ip Gmbh TIENILPIRI (MI) DINILPIRAZOLES
IN2014CN02475A (en) 2011-10-06 2015-06-19 Bayer Ip Gmbh
RU2616293C2 (en) 2011-10-06 2017-04-14 Байер Интеллектуэль Проперти Гмбх Geterocyclilpyridinylpyrazols as fungicidal agents
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EP2914591B1 (en) * 2012-11-03 2017-10-11 Boehringer Ingelheim International GmbH Inhibitors of cytomegalovirus
EA034822B9 (en) 2014-10-08 2020-10-23 РЭДКС ФАРМА ПиЭлСи N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE Wnt SIGNALLING PATHWAY
KR102476667B1 (en) * 2014-10-08 2022-12-09 레드엑스 파마 피엘씨 N-pyridinyl acetamide derivatives as wnt signalling pathway inhibitors
WO2020120673A1 (en) * 2018-12-13 2020-06-18 Intervet International B.V. Process for preparing 1-[(3r,4s)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl)amino]p yrazole-4-carboxamide
CN115417809A (en) * 2022-09-05 2022-12-02 天津药明康德新药开发有限公司 Preparation method of 4, 4-dipyrrole-2, 2-bipyridine
CN116836153A (en) * 2023-06-16 2023-10-03 厦门大学 CDK9-Cyclin T1 protein interaction inhibitor and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4004012A (en) * 1975-10-14 1977-01-18 Sterling Drug Inc. 3-Cyano-5-(pyridinyl)-2(1H)-pyridinones
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
PT1042293E (en) * 1997-12-19 2008-04-18 Amgen Inc Substituted pyridine and pyridazine compounds and their pharmaceutical use
MXPA03005001A (en) * 2000-12-05 2003-09-05 Vertex Pharma Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases.

Also Published As

Publication number Publication date
AR042316A1 (en) 2005-06-15
WO2004052880A1 (en) 2004-06-24
TW200417546A (en) 2004-09-16
SE0203654D0 (en) 2002-12-09

Similar Documents

Publication Publication Date Title
AU2003302919A1 (en) Pyridine derivatives as jnk inhibitors and their use
HUS1400047I1 (en) Quinoline derivatives and their use as mycobacterial inhibitors
AU2003266321A1 (en) Tetrahydropyrimidine-2-one derivatives and their uses
IL173986A0 (en) 2-pyridone derivatives as netrophil elastase inhibitors and their use
AU2003235676A1 (en) Tricyclic-bis-enone derivatives and methods of use thereof
AU2003298514A1 (en) Methods and compositions using cholinesterase inhibitors
AU2003280188A1 (en) Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
AU2003259749A1 (en) 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
PL372756A1 (en) Nicotinamide derivatives useful as pde4 inhibitors
AU2003249909A1 (en) Phenoxypropenylphenyl derivatives and their use as herbicides
AU2003232848A1 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
AU2003303388A1 (en) Triptolide derivatives and their use
AU2003202116A1 (en) Nicotinamide derivatives useful as pde4 inhibitors
AU2003289386A1 (en) Jnk inhibitors
AU2003215756A1 (en) Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors
AU2003292381A1 (en) Naphthyridine derivatives and their use as fungicides
AU2003211427A1 (en) Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same
AU2003297612A1 (en) 2-substituted-3-propenamide derivatives and methods of using the same
AU2003258942A1 (en) Imidazolidinedione-derivatives and their use as metalloproteinase inhibitors
AU2003281691A1 (en) Furoisoquinoline derivative and use thereof
AU2003212515A1 (en) Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
AU2003218715A1 (en) Azepane derivatives and their use as atk1 inhibitors
AU2003205963A1 (en) Azaphenylalanine derivatives and their use as antithrombotic agents
AU2003900495A0 (en) Aroylhydrazone derivatives and therapeutic uses thereof
AU2003245524A1 (en) Cryosurgery compositions and methods

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase